TTrialPathMatch Me to Trials
← Back to trials
RecruitingMuscular Dystrophy, Facioscapulohumeral

Clenbuterol to Target DUX4 in FSHD

Eligible age

18–75 yrs

Accepts

All genders

Locations

3 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.

Sponsor: Jeffrey Statland

You may qualify if…

  • ✓ Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation
  • ✓ between 18 and 75 years of age
  • ✓ with a clinical severity score between 0 and 10
  • ✓ Able to walk 30ft without support of another person
  • ✓ Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy
  • ✓ willing and able to provide informed consent
  • ✓ agree to follow the contraceptive requirement for duration of the study

You may not qualify if…

  • ✕ Pregnant or planning to become pregnant during the conduct of the study
  • ✕ have a poorly controlled medical condition
  • ✕ Were involved in a study of an experimental agent within 3 months of enrollment
  • ✕ Are taking beta-blockers or anabolic agent or potassium wasting diuretics
  • ✕ Are taking or are planning to take a GLP-1 Agonist during trial
  • ✕ have any condition or contraindication which would interfere with testing or preclude use of beta-agonist
  • ✕ Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated
  • ✕ Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose

Where it's recruiting

Kansas

Kansas City

New York

Rochester

Washington

Seattle

Source: ClinicalTrials.gov · NCT06721299 · last updated 2026-02-25